Vendor Intelligence Report: Jinan Elitepeptide Chemical JEC JCE

Published 3 Jul 2026. 22-page investigative report on who is behind Jinan Elitepeptide Chemical JEC JCE: corporate records, ownership, affiliate networks, and the vendor's lab-testing record. The first 4 pages are free to read on this page.

Researched and published by Finnrick Analytics. Reports draw on corporate records, affiliate-network analysis, and Finnrick's own laboratory testing record; vendors can challenge findings through the formal objections process at finnrick.com/vendor-support/objections.

Executive summary

Across 10 Finnrick lab tests, JEC/JCE records 10 pass / 0 fail — an overall pass rate of 100%. The chemistry signal is real but narrow: Tirzepatide and Retatrutide are the only Finnrick-tested products, both with favorable historical results, while the July 2026 push into KLOW80, GHK-CU, MOTS-C, and Tesa10/Tesamorelin sits outside the independent test record. Ratings also contract under stricter fill-and-purity scoring, making this a product-specific gray-market signal rather than pharmaceutical-grade assurance.

The operational picture is less clean than the pass record. JEC is active again through GLP-1 Forum promotion and chat channels, but the original domain no longer resolves, the old forum anchor is Cloudflare-blocked, the custom-domain email has been replaced by Gmail, and Discord infrastructure was banned and rebuilt. Chinese registry searches did not verify the claimed company name, and a Thailand-code WhatsApp number complicates the simple Jinan-manufacturer story.

The most important buyer read is directional. JEC is most defensible for buyers specifically comparing Tirzepatide or Retatrutide options, after confirming they are dealing with the same seller and a current, verifiable lot COA. It is weakly supported to unsupported for the newly advertised catalog and carries separate chain-of-custody concerns: Atlantic reporting tied JEC to disguised Retatrutide shipping with unlabeled vials, and the vendor-linked Janoshik Tesa10 report could not be independently opened during collection.

Inside the full report:

  • Per-product Finnrick interpretation and methodology-divergence charts for Tirzepatide and Retatrutide
  • Public timeline from domain registration to the July 2026 US-warehouse promotion
  • Corporate-registry search results, contact-bundle analysis, and the Thailand WhatsApp discrepancy
  • Channel-authentication review of the expired domain, blocked forum thread, Gmail shift, Telegram, WhatsApp, Discord, and Peptide Chat
  • Evidence review of the Atlantic unlabeled-vial shipment, Janoshik Tesa10 verification barrier, and unverified US-warehouse claim

Risk assessment

  • Covert-shipping and unlabeled-vial risk — high: The Atlantic documented Retatrutide from JEC in disguised consumer/cosmetic packaging with unlabeled vials, undermining identity and lot traceability.
  • Channel-authentication and brand-confusion risk — high: jce111.com is not resolving, the original forum thread is Cloudflare-blocked, contact shifted to Gmail/new Discord, and JEC provides no stable official-channel or anti-counterfeit list.
  • Untested expanded-catalog risk — high: KLOW80, GHK-CU50, MOTS-C10, MOTS-C40 and Tesa10/Tesamorelin have no independent Finnrick tests; current Finnrick support covers only Tirzepatide and Retatrutide.
  • Unverified US warehouse fulfillment risk — medium: JEC advertises local US warehouse shipping in 3-7 working days, but no warehouse address, tracking sample, domestic entity or manifest was verified.
  • Corporate identity and location-verification risk — medium: No matching corporate or trade registry record was located under searched names, no responsible officers/address were verified, and the main WhatsApp number uses Thailand +66.
  • COA-verification and sterile/endotoxin data gap — medium: The Tesa10 Janoshik link could not be independently opened during OSINT collection, and supplied purity/fill claims do not establish sterility or endotoxin control for injectable use.